These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Jacobson MA; Zegans M; Pavan PR; O'Donnell JJ; Sattler F; Rao N; Owens S; Pollard R Lancet; 1997 May; 349(9063):1443-5. PubMed ID: 9164318 [TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Whitcup SM JAMA; 2000 Feb; 283(5):653-7. PubMed ID: 10665706 [TBL] [Abstract][Full Text] [Related]
4. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. Macdonald JC; Torriani FJ; Morse LS; Karavellas MP; Reed JB; Freeman WR J Infect Dis; 1998 May; 177(5):1182-7. PubMed ID: 9593001 [TBL] [Abstract][Full Text] [Related]
5. Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy. Di Perri G; Vento S; Mazzi R; Bonora S; Bonora A; Trevenzoli M; Allegranzi B; Carretta G; Lanzafame M; Pizzighella S; Concia E J Infect; 1999 Nov; 39(3):193-7. PubMed ID: 10714794 [TBL] [Abstract][Full Text] [Related]
6. Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease. Verbraak FD; Boom R; Wertheim-van Dillen PM; van den Horn GJ; Kijlstra A; de Smet MD Br J Ophthalmol; 1999 Oct; 83(10):1186-9. PubMed ID: 10502584 [TBL] [Abstract][Full Text] [Related]
7. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Vrabec TR; Baldassano VF; Whitcup SM Ophthalmology; 1998 Jul; 105(7):1259-64. PubMed ID: 9663231 [TBL] [Abstract][Full Text] [Related]
9. Highly active antiretroviral therapy-associated regression of cytomegalovirus retinitis: long-Term results in a small case series. Reed JB; Briggs JW; McDonald JC; Freeman WR; Morse LS Retina; 2001; 21(4):339-43. PubMed ID: 11508879 [TBL] [Abstract][Full Text] [Related]
10. Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy. Berenguer J; González J; Pulido F; Padilla B; Casado JL; Rubio R; Arribas JR; Clin Infect Dis; 2002 Feb; 34(3):394-7. PubMed ID: 11753827 [TBL] [Abstract][Full Text] [Related]
11. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy. Song MK; Karavellas MP; MacDonald JC; Plummer DJ; Freeman WR Retina; 2000; 20(2):151-5. PubMed ID: 10783947 [TBL] [Abstract][Full Text] [Related]
12. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. Jouan M; Savès M; Tubiana R; Carcelain G; Cassoux N; Aubron-Olivier C; Fillet AM; Nciri M; Sénéchal B; Chêne G; Tural C; Lasry S; Autran B; Katlama C; AIDS; 2001 Jan; 15(1):23-31. PubMed ID: 11192865 [TBL] [Abstract][Full Text] [Related]
13. Protease inhibitors linked to drop in CMV retinitis. AIDS Alert; 1997 Aug; 12(8):92-4. PubMed ID: 11364475 [TBL] [Abstract][Full Text] [Related]
14. Ophthalmic manifestations of HIV in the highly active anti-retroviral therapy era. Mowatt L West Indian Med J; 2013; 62(4):305-12. PubMed ID: 24756590 [TBL] [Abstract][Full Text] [Related]
15. Sustained cytomegalovirus-specific CD4+ T cell response associated with prevention of recurrence of cytomegalovirus retinitis without secondary prophylaxis after highly active antiretroviral therapy in patients with AIDS. Tanaka M; Yasuoka C; Genka I; Tachikawa N; Kikuchi Y; Teruya K; Yasuoka A; Hirabayashi Y; Kimura S; Oka S AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1749-56. PubMed ID: 11788026 [TBL] [Abstract][Full Text] [Related]
16. Control of cytomegalovirus retinitis after combination antiretroviral therapy. Ruhswurm I; Ries E; Krepler K; Derbolav A; Rieger A; Armbruster C; Wedrich A Acta Ophthalmol Scand; 1999 Aug; 77(4):471-3. PubMed ID: 10463426 [TBL] [Abstract][Full Text] [Related]
17. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. Komanduri KV; Feinberg J; Hutchins RK; Frame RD; Schmidt DK; Viswanathan MN; Lalezari JP; McCune JM J Infect Dis; 2001 Apr; 183(8):1285-9. PubMed ID: 11262214 [TBL] [Abstract][Full Text] [Related]
18. A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy. Green H; Hay P; Dunn DT; McCormack S; HIV Med; 2004 Jul; 5(4):278-83. PubMed ID: 15236617 [TBL] [Abstract][Full Text] [Related]
19. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Jabs DA; Van Natta ML; Thorne JE; Weinberg DV; Meredith TA; Kuppermann BD; Sepkowitz K; Li HK; Ophthalmology; 2004 Dec; 111(12):2232-9. PubMed ID: 15582079 [TBL] [Abstract][Full Text] [Related]
20. Cessation of anti-CMV therapy in patients with CMV retinitis. Dunn JP Hopkins HIV Rep; 1998 Mar; 10(2):11. PubMed ID: 11365137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]